GMP Manufacturing and IND Enabling Studies of Extended-Release PNA5: ANovel Therapeutic for Treating Cognitive Impairment in Patients at-risk for Alzheimer's Disease-Related Dementias and Vascular
Department of Health and Human Services — National Institutes of Health
Opportunity #: 1R43AG085713-01
Description
SBIR Phase Phase I award: "GMP Manufacturing and IND Enabling Studies of Extended-Release PNA5: ANovel Therapeutic for Treating Cognitive Impairment in Patients at-risk for Alzheimer's Disease-Related Dementias and Vascular" awarded to Proneurogen, Inc in Tucson, Arizona. Funded by Department of Health and Human Services (National Institutes of Health). Award amount: $499,545. The SBIR/STTR programs fund innovative research and development by small businesses, with Phase I for feasibility studies and Phase II for full R&D.
Eligible Applicants
Apply on Grants.gov
Always verify details and apply through the official Grants.gov portal. Information here may not reflect the latest changes.
View on Grants.gov